nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—KIT—bone cancer	0.403	0.783	CbGaD
Dasatinib—CYP3A4—bone cancer	0.112	0.217	CbGaD
Dasatinib—CYP1B1—Doxorubicin—bone cancer	0.0249	0.24	CbGbCtD
Dasatinib—ABCG2—Carboplatin—bone cancer	0.0207	0.199	CbGbCtD
Dasatinib—ABCG2—Cisplatin—bone cancer	0.0176	0.17	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—bone cancer	0.0118	0.114	CbGbCtD
Dasatinib—ABCG2—Methotrexate—bone cancer	0.0115	0.11	CbGbCtD
Dasatinib—SRMS—knee—bone cancer	0.00915	0.145	CbGeAlD
Dasatinib—ABCB1—Cisplatin—bone cancer	0.00636	0.0613	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—bone cancer	0.00426	0.0411	CbGbCtD
Dasatinib—ABCB1—Methotrexate—bone cancer	0.00413	0.0398	CbGbCtD
Dasatinib—SRC—periosteum—bone cancer	0.00263	0.0416	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—bone cancer	0.00256	0.0246	CbGbCtD
Dasatinib—CSF1R—periosteum—bone cancer	0.00236	0.0373	CbGeAlD
Dasatinib—MYT1—spinal cord—bone cancer	0.00136	0.0214	CbGeAlD
Dasatinib—SIK2—connective tissue—bone cancer	0.00121	0.0191	CbGeAlD
Dasatinib—TEC—tendon—bone cancer	0.0012	0.0189	CbGeAlD
Dasatinib—SRMS—connective tissue—bone cancer	0.0011	0.0173	CbGeAlD
Dasatinib—STAT5B—connective tissue—bone cancer	0.00102	0.0161	CbGeAlD
Dasatinib—EPHB1—tendon—bone cancer	0.000939	0.0148	CbGeAlD
Dasatinib—LYN—connective tissue—bone cancer	0.000828	0.0131	CbGeAlD
Dasatinib—BTK—connective tissue—bone cancer	0.000811	0.0128	CbGeAlD
Dasatinib—PKMYT1—bone marrow—bone cancer	0.000783	0.0124	CbGeAlD
Dasatinib—BMX—bone marrow—bone cancer	0.000764	0.0121	CbGeAlD
Dasatinib—TESK1—connective tissue—bone cancer	0.000752	0.0119	CbGeAlD
Dasatinib—SRMS—bone marrow—bone cancer	0.000731	0.0115	CbGeAlD
Dasatinib—TXK—bone marrow—bone cancer	0.000723	0.0114	CbGeAlD
Dasatinib—CSK—connective tissue—bone cancer	0.000688	0.0109	CbGeAlD
Dasatinib—STAT5B—bone marrow—bone cancer	0.000677	0.0107	CbGeAlD
Dasatinib—RIPK2—connective tissue—bone cancer	0.000639	0.0101	CbGeAlD
Dasatinib—SIK3—tendon—bone cancer	0.000629	0.00992	CbGeAlD
Dasatinib—SIK1—connective tissue—bone cancer	0.000624	0.00985	CbGeAlD
Dasatinib—ERBB3—connective tissue—bone cancer	0.000612	0.00966	CbGeAlD
Dasatinib—MAP3K2—connective tissue—bone cancer	0.000606	0.00956	CbGeAlD
Dasatinib—ZAK—tendon—bone cancer	0.000584	0.00923	CbGeAlD
Dasatinib—MAPK14—connective tissue—bone cancer	0.00057	0.00899	CbGeAlD
Dasatinib—BTK—tendon—bone cancer	0.000557	0.0088	CbGeAlD
Dasatinib—EPHA5—spinal cord—bone cancer	0.000552	0.00871	CbGeAlD
Dasatinib—BTK—bone marrow—bone cancer	0.00054	0.00853	CbGeAlD
Dasatinib—EPHB4—connective tissue—bone cancer	0.00054	0.00852	CbGeAlD
Dasatinib—BTK—spinal cord—bone cancer	0.000538	0.00849	CbGeAlD
Dasatinib—JAK2—connective tissue—bone cancer	0.000536	0.00846	CbGeAlD
Dasatinib—FYN—connective tissue—bone cancer	0.000529	0.00835	CbGeAlD
Dasatinib—TESK1—tendon—bone cancer	0.000517	0.00816	CbGeAlD
Dasatinib—STK36—tendon—bone cancer	0.000508	0.00803	CbGeAlD
Dasatinib—TESK1—spinal cord—bone cancer	0.000498	0.00787	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—bone cancer	0.000493	0.127	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—bone cancer	0.000493	0.127	CbGdCrCtD
Dasatinib—EPHB3—spinal cord—bone cancer	0.00049	0.00774	CbGeAlD
Dasatinib—YES1—connective tissue—bone cancer	0.000477	0.00753	CbGeAlD
Dasatinib—STK35—tendon—bone cancer	0.000476	0.00752	CbGeAlD
Dasatinib—LIMK2—spinal cord—bone cancer	0.000474	0.00748	CbGeAlD
Dasatinib—CSK—tendon—bone cancer	0.000473	0.00747	CbGeAlD
Dasatinib—PDGFRA—connective tissue—bone cancer	0.000468	0.00739	CbGeAlD
Dasatinib—HCK—tendon—bone cancer	0.000467	0.00738	CbGeAlD
Dasatinib—ABL2—tendon—bone cancer	0.000464	0.00733	CbGeAlD
Dasatinib—SRC—connective tissue—bone cancer	0.000459	0.00725	CbGeAlD
Dasatinib—CSK—bone marrow—bone cancer	0.000458	0.00724	CbGeAlD
Dasatinib—CSK—spinal cord—bone cancer	0.000456	0.00721	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—bone cancer	0.000456	0.117	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—bone cancer	0.000456	0.117	CbGdCrCtD
Dasatinib—HCK—bone marrow—bone cancer	0.000453	0.00714	CbGeAlD
Dasatinib—HCK—spinal cord—bone cancer	0.000451	0.00711	CbGeAlD
Dasatinib—RIPK2—tendon—bone cancer	0.000439	0.00693	CbGeAlD
Dasatinib—SIK1—tendon—bone cancer	0.000429	0.00677	CbGeAlD
Dasatinib—RIPK2—bone marrow—bone cancer	0.000425	0.00672	CbGeAlD
Dasatinib—EPHA4—tendon—bone cancer	0.000425	0.0067	CbGeAlD
Dasatinib—RIPK2—spinal cord—bone cancer	0.000424	0.00669	CbGeAlD
Dasatinib—SIK1—bone marrow—bone cancer	0.000415	0.00656	CbGeAlD
Dasatinib—SIK1—spinal cord—bone cancer	0.000414	0.00653	CbGeAlD
Dasatinib—CSF1R—connective tissue—bone cancer	0.000412	0.00651	CbGeAlD
Dasatinib—ERBB3—spinal cord—bone cancer	0.000405	0.0064	CbGeAlD
Dasatinib—MAP3K2—bone marrow—bone cancer	0.000403	0.00637	CbGeAlD
Dasatinib—MAPK14—tendon—bone cancer	0.000391	0.00618	CbGeAlD
Dasatinib—FGR—tendon—bone cancer	0.00039	0.00616	CbGeAlD
Dasatinib—MAPK14—bone marrow—bone cancer	0.000379	0.00599	CbGeAlD
Dasatinib—FGR—bone marrow—bone cancer	0.000378	0.00596	CbGeAlD
Dasatinib—LCK—bone marrow—bone cancer	0.000378	0.00596	CbGeAlD
Dasatinib—MAPK14—spinal cord—bone cancer	0.000378	0.00596	CbGeAlD
Dasatinib—KIT—connective tissue—bone cancer	0.000374	0.00591	CbGeAlD
Dasatinib—EPHB4—tendon—bone cancer	0.000371	0.00586	CbGeAlD
Dasatinib—JAK2—tendon—bone cancer	0.000368	0.00582	CbGeAlD
Dasatinib—PDGFRB—connective tissue—bone cancer	0.000366	0.00577	CbGeAlD
Dasatinib—EPHA2—tendon—bone cancer	0.000364	0.00575	CbGeAlD
Dasatinib—FYN—tendon—bone cancer	0.000363	0.00574	CbGeAlD
Dasatinib—EPHB4—bone marrow—bone cancer	0.000359	0.00568	CbGeAlD
Dasatinib—EPHB4—spinal cord—bone cancer	0.000358	0.00565	CbGeAlD
Dasatinib—JAK2—bone marrow—bone cancer	0.000357	0.00564	CbGeAlD
Dasatinib—JAK2—spinal cord—bone cancer	0.000355	0.00561	CbGeAlD
Dasatinib—MAP4K5—tendon—bone cancer	0.000355	0.00561	CbGeAlD
Dasatinib—MAP3K3—tendon—bone cancer	0.000355	0.00561	CbGeAlD
Dasatinib—FYN—bone marrow—bone cancer	0.000352	0.00556	CbGeAlD
Dasatinib—FYN—spinal cord—bone cancer	0.000351	0.00553	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000344	0.0886	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000344	0.0886	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000344	0.0886	CbGdCrCtD
Dasatinib—MAP4K5—bone marrow—bone cancer	0.000344	0.00543	CbGeAlD
Dasatinib—MAP3K3—bone marrow—bone cancer	0.000344	0.00543	CbGeAlD
Dasatinib—MAP4K5—spinal cord—bone cancer	0.000343	0.00541	CbGeAlD
Dasatinib—MAP3K3—spinal cord—bone cancer	0.000343	0.00541	CbGeAlD
Dasatinib—EPHB6—tendon—bone cancer	0.000339	0.00536	CbGeAlD
Dasatinib—YES1—tendon—bone cancer	0.000328	0.00518	CbGeAlD
Dasatinib—EPHB6—spinal cord—bone cancer	0.000327	0.00517	CbGeAlD
Dasatinib—ABL1—connective tissue—bone cancer	0.000326	0.00514	CbGeAlD
Dasatinib—PDGFRA—tendon—bone cancer	0.000322	0.00508	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000318	0.0819	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000318	0.0819	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000318	0.0819	CbGdCrCtD
Dasatinib—YES1—bone marrow—bone cancer	0.000318	0.00502	CbGeAlD
Dasatinib—YES1—spinal cord—bone cancer	0.000316	0.00499	CbGeAlD
Dasatinib—PDGFRA—spinal cord—bone cancer	0.00031	0.0049	CbGeAlD
Dasatinib—SRC—spinal cord—bone cancer	0.000304	0.00481	CbGeAlD
Dasatinib—MAP2K5—tendon—bone cancer	0.00029	0.00458	CbGeAlD
Dasatinib—CSF1R—tendon—bone cancer	0.000283	0.00447	CbGeAlD
Dasatinib—MAP2K5—spinal cord—bone cancer	0.00028	0.00442	CbGeAlD
Dasatinib—CYP1B1—connective tissue—bone cancer	0.000276	0.00436	CbGeAlD
Dasatinib—CSF1R—bone marrow—bone cancer	0.000274	0.00433	CbGeAlD
Dasatinib—CSF1R—spinal cord—bone cancer	0.000273	0.00431	CbGeAlD
Dasatinib—PDGFRB—tendon—bone cancer	0.000251	0.00397	CbGeAlD
Dasatinib—KIT—bone marrow—bone cancer	0.000249	0.00393	CbGeAlD
Dasatinib—KIT—spinal cord—bone cancer	0.000248	0.00392	CbGeAlD
Dasatinib—PDGFRB—bone marrow—bone cancer	0.000243	0.00384	CbGeAlD
Dasatinib—PDGFRB—spinal cord—bone cancer	0.000242	0.00383	CbGeAlD
Dasatinib—ABL1—tendon—bone cancer	0.000224	0.00354	CbGeAlD
Dasatinib—ABL1—bone marrow—bone cancer	0.000217	0.00342	CbGeAlD
Dasatinib—ABL1—spinal cord—bone cancer	0.000216	0.00341	CbGeAlD
Dasatinib—CYP1B1—tendon—bone cancer	0.00019	0.00299	CbGeAlD
Dasatinib—Infestation—Epirubicin—bone cancer	0.000138	0.00102	CcSEcCtD
Dasatinib—ABCG2—bone marrow—bone cancer	0.000137	0.00216	CbGeAlD
Dasatinib—ABCG2—spinal cord—bone cancer	0.000136	0.00215	CbGeAlD
Dasatinib—Pancytopenia—Doxorubicin—bone cancer	0.000136	0.00101	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—bone cancer	0.000135	0.00101	CcSEcCtD
Dasatinib—Body temperature increased—Cisplatin—bone cancer	0.000135	0.001	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—bone cancer	0.000135	0.001	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—bone cancer	0.000134	0.000997	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—bone cancer	0.000134	0.000994	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—bone cancer	0.000134	0.000993	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000133	0.000987	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—bone cancer	0.000133	0.000986	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—bone cancer	0.000132	0.000981	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—bone cancer	0.000132	0.000981	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—bone cancer	0.000132	0.000981	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—bone cancer	0.000131	0.000975	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—bone cancer	0.000131	0.000969	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—bone cancer	0.000131	0.000969	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—bone cancer	0.00013	0.000968	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—bone cancer	0.00013	0.000966	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—bone cancer	0.00013	0.000965	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—bone cancer	0.00013	0.000962	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—bone cancer	0.000129	0.00096	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—bone cancer	0.000128	0.000952	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—bone cancer	0.000127	0.000947	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—bone cancer	0.000127	0.000947	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—bone cancer	0.000127	0.000946	CcSEcCtD
Dasatinib—Hypersensitivity—Cisplatin—bone cancer	0.000126	0.000936	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—bone cancer	0.000125	0.000931	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—bone cancer	0.000125	0.000928	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—bone cancer	0.000125	0.000928	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—bone cancer	0.000124	0.000923	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—bone cancer	0.000124	0.000923	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—bone cancer	0.000124	0.00092	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—bone cancer	0.000124	0.000918	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—bone cancer	0.000124	0.000918	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—bone cancer	0.000124	0.000917	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—bone cancer	0.000123	0.000915	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—bone cancer	0.000123	0.000912	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—bone cancer	0.000123	0.000911	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—bone cancer	0.000122	0.000907	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—bone cancer	0.000122	0.000905	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—bone cancer	0.000122	0.000903	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—bone cancer	0.000122	0.000902	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—bone cancer	0.000121	0.0009	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000121	0.000895	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—bone cancer	0.00012	0.000893	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—bone cancer	0.00012	0.00089	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—bone cancer	0.000119	0.000886	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—bone cancer	0.000119	0.000885	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—bone cancer	0.000119	0.000884	CcSEcCtD
Dasatinib—Chills—Methotrexate—bone cancer	0.000119	0.000881	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—bone cancer	0.000117	0.000869	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—bone cancer	0.000117	0.000868	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—bone cancer	0.000117	0.000867	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—bone cancer	0.000116	0.00086	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—bone cancer	0.000116	0.000858	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—bone cancer	0.000115	0.000856	CcSEcCtD
Dasatinib—Erythema—Methotrexate—bone cancer	0.000115	0.000854	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—bone cancer	0.000115	0.000854	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—bone cancer	0.000115	0.000854	CcSEcCtD
Dasatinib—Flushing—Epirubicin—bone cancer	0.000115	0.000852	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—bone cancer	0.000115	0.000852	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—bone cancer	0.000114	0.00085	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—bone cancer	0.000114	0.00085	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—bone cancer	0.000113	0.000839	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—bone cancer	0.000113	0.000837	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—bone cancer	0.000113	0.000837	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—bone cancer	0.000112	0.000835	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—bone cancer	0.000112	0.000833	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—bone cancer	0.000112	0.000833	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—bone cancer	0.000112	0.00083	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—bone cancer	0.000111	0.000828	CcSEcCtD
Dasatinib—Chills—Epirubicin—bone cancer	0.000111	0.000824	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—bone cancer	0.00011	0.00082	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—bone cancer	0.00011	0.000819	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—bone cancer	0.000109	0.000812	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—bone cancer	0.000109	0.000808	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—bone cancer	0.000108	0.000805	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—bone cancer	0.000108	0.000805	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—bone cancer	0.000108	0.000803	CcSEcCtD
Dasatinib—Rash—Cisplatin—bone cancer	0.000108	0.000801	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—bone cancer	0.000108	0.0008	CcSEcCtD
Dasatinib—Erythema—Epirubicin—bone cancer	0.000108	0.000799	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—bone cancer	0.000108	0.000799	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—bone cancer	0.000107	0.000794	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—bone cancer	0.000107	0.000793	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—bone cancer	0.000107	0.000792	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—bone cancer	0.000106	0.00079	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—bone cancer	0.000106	0.000789	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—bone cancer	0.000106	0.000789	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—bone cancer	0.000105	0.000783	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—bone cancer	0.000104	0.000771	CcSEcCtD
Dasatinib—Malaise—Methotrexate—bone cancer	0.000104	0.00077	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—bone cancer	0.000104	0.000769	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—bone cancer	0.000103	0.000768	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—bone cancer	0.000103	0.000768	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—bone cancer	0.000103	0.000766	CcSEcCtD
Dasatinib—Chills—Doxorubicin—bone cancer	0.000103	0.000762	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—bone cancer	0.000102	0.000759	CcSEcCtD
Dasatinib—Nausea—Cisplatin—bone cancer	0.000102	0.000755	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—bone cancer	0.000101	0.000753	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—bone cancer	0.000101	0.000751	CcSEcCtD
Dasatinib—Cough—Methotrexate—bone cancer	0.0001	0.000745	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—bone cancer	0.0001	0.000744	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—bone cancer	9.99e-05	0.000742	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—bone cancer	9.97e-05	0.00074	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—bone cancer	9.96e-05	0.00074	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—bone cancer	9.96e-05	0.00074	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—bone cancer	9.95e-05	0.000739	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—bone cancer	9.79e-05	0.000727	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—bone cancer	9.79e-05	0.000727	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—bone cancer	9.79e-05	0.000727	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—bone cancer	9.76e-05	0.000724	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.73e-05	0.000722	CcSEcCtD
Dasatinib—Malaise—Epirubicin—bone cancer	9.71e-05	0.000721	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—bone cancer	9.68e-05	0.000719	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—bone cancer	9.67e-05	0.000718	CcSEcCtD
Dasatinib—Syncope—Epirubicin—bone cancer	9.66e-05	0.000717	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—bone cancer	9.58e-05	0.000711	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—bone cancer	9.51e-05	0.000707	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—bone cancer	9.47e-05	0.000703	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—bone cancer	9.46e-05	0.000703	CcSEcCtD
Dasatinib—Cough—Epirubicin—bone cancer	9.4e-05	0.000698	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—bone cancer	9.39e-05	0.000697	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—bone cancer	9.33e-05	0.000693	CcSEcCtD
Dasatinib—Infection—Methotrexate—bone cancer	9.33e-05	0.000693	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—bone cancer	9.3e-05	0.00069	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—bone cancer	9.24e-05	0.000686	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—bone cancer	9.21e-05	0.000684	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—bone cancer	9.21e-05	0.000684	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—bone cancer	9.19e-05	0.000683	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—bone cancer	9.17e-05	0.000681	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—bone cancer	9.17e-05	0.000681	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—bone cancer	9.17e-05	0.000681	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—bone cancer	9.13e-05	0.000678	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—bone cancer	9.12e-05	0.000677	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	9.1e-05	0.000676	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—bone cancer	9.08e-05	0.000674	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—bone cancer	9.06e-05	0.000672	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—bone cancer	8.98e-05	0.000667	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—bone cancer	8.95e-05	0.000665	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—bone cancer	8.95e-05	0.000665	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—bone cancer	8.93e-05	0.000663	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—bone cancer	8.86e-05	0.000658	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—bone cancer	8.8e-05	0.000654	CcSEcCtD
Dasatinib—Oedema—Epirubicin—bone cancer	8.79e-05	0.000652	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—bone cancer	8.77e-05	0.000651	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—bone cancer	8.76e-05	0.00065	CcSEcCtD
Dasatinib—Infection—Epirubicin—bone cancer	8.73e-05	0.000648	CcSEcCtD
Dasatinib—Cough—Doxorubicin—bone cancer	8.69e-05	0.000646	CcSEcCtD
Dasatinib—Shock—Epirubicin—bone cancer	8.64e-05	0.000642	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—bone cancer	8.63e-05	0.000641	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—bone cancer	8.62e-05	0.00064	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—bone cancer	8.6e-05	0.000639	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—bone cancer	8.6e-05	0.000639	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—bone cancer	8.58e-05	0.000637	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—bone cancer	8.55e-05	0.000635	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—bone cancer	8.53e-05	0.000634	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—bone cancer	8.49e-05	0.000631	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—bone cancer	8.49e-05	0.000631	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—bone cancer	8.48e-05	0.00063	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—bone cancer	8.48e-05	0.00063	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—bone cancer	8.48e-05	0.00063	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—bone cancer	8.45e-05	0.000628	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.42e-05	0.000625	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—bone cancer	8.38e-05	0.000622	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—bone cancer	8.38e-05	0.000622	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—bone cancer	8.37e-05	0.000622	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—bone cancer	8.35e-05	0.00062	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—bone cancer	8.27e-05	0.000614	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—bone cancer	8.21e-05	0.00061	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—bone cancer	8.2e-05	0.000609	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—bone cancer	8.16e-05	0.000606	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—bone cancer	8.13e-05	0.000604	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—bone cancer	8.11e-05	0.000602	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—bone cancer	8.1e-05	0.000601	CcSEcCtD
Dasatinib—Infection—Doxorubicin—bone cancer	8.08e-05	0.0006	CcSEcCtD
Dasatinib—Pain—Methotrexate—bone cancer	8.03e-05	0.000596	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—bone cancer	8.01e-05	0.000594	CcSEcCtD
Dasatinib—Shock—Doxorubicin—bone cancer	8e-05	0.000594	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—bone cancer	7.97e-05	0.000592	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—bone cancer	7.96e-05	0.000591	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—bone cancer	7.95e-05	0.00059	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—bone cancer	7.93e-05	0.000589	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—bone cancer	7.9e-05	0.000586	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—bone cancer	7.86e-05	0.000584	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—bone cancer	7.83e-05	0.000582	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—bone cancer	7.81e-05	0.00058	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—bone cancer	7.75e-05	0.000575	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—bone cancer	7.74e-05	0.000575	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—bone cancer	7.73e-05	0.000574	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—bone cancer	7.68e-05	0.00057	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—bone cancer	7.64e-05	0.000567	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—bone cancer	7.6e-05	0.000564	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—bone cancer	7.59e-05	0.000563	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—bone cancer	7.58e-05	0.000563	CcSEcCtD
Dasatinib—Pain—Epirubicin—bone cancer	7.51e-05	0.000558	CcSEcCtD
Dasatinib—Constipation—Epirubicin—bone cancer	7.51e-05	0.000558	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—bone cancer	7.46e-05	0.000554	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—bone cancer	7.42e-05	0.000551	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—bone cancer	7.42e-05	0.000551	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.41e-05	0.00055	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—bone cancer	7.35e-05	0.000546	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—bone cancer	7.25e-05	0.000538	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—bone cancer	7.24e-05	0.000538	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—bone cancer	7.23e-05	0.000537	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—bone cancer	7.19e-05	0.000534	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—bone cancer	7.16e-05	0.000531	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—bone cancer	7.07e-05	0.000525	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—bone cancer	7.02e-05	0.000521	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—bone cancer	7.01e-05	0.000521	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—bone cancer	6.98e-05	0.000518	CcSEcCtD
Dasatinib—Pain—Doxorubicin—bone cancer	6.95e-05	0.000516	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—bone cancer	6.95e-05	0.000516	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—bone cancer	6.95e-05	0.000516	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—bone cancer	6.95e-05	0.000516	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—bone cancer	6.92e-05	0.000514	CcSEcCtD
Dasatinib—ABCB1—bone marrow—bone cancer	6.75e-05	0.00106	CbGeAlD
Dasatinib—Asthenia—Methotrexate—bone cancer	6.74e-05	0.0005	CcSEcCtD
Dasatinib—ABCB1—spinal cord—bone cancer	6.72e-05	0.00106	CbGeAlD
Dasatinib—Feeling abnormal—Doxorubicin—bone cancer	6.7e-05	0.000498	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—bone cancer	6.65e-05	0.000494	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—bone cancer	6.64e-05	0.000493	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—bone cancer	6.47e-05	0.000481	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—bone cancer	6.46e-05	0.00048	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—bone cancer	6.43e-05	0.000477	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—bone cancer	6.43e-05	0.000477	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—bone cancer	6.42e-05	0.000477	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—bone cancer	6.3e-05	0.000468	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—bone cancer	6.22e-05	0.000462	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—bone cancer	6.21e-05	0.000461	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—bone cancer	6.01e-05	0.000446	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—bone cancer	5.99e-05	0.000445	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—bone cancer	5.97e-05	0.000443	CcSEcCtD
Dasatinib—Rash—Methotrexate—bone cancer	5.92e-05	0.00044	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—bone cancer	5.91e-05	0.000439	CcSEcCtD
Dasatinib—Headache—Methotrexate—bone cancer	5.88e-05	0.000437	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—bone cancer	5.83e-05	0.000433	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—bone cancer	5.81e-05	0.000431	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—bone cancer	5.75e-05	0.000427	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—bone cancer	5.59e-05	0.000415	CcSEcCtD
Dasatinib—Nausea—Methotrexate—bone cancer	5.58e-05	0.000414	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—bone cancer	5.56e-05	0.000413	CcSEcCtD
Dasatinib—Rash—Epirubicin—bone cancer	5.54e-05	0.000411	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—bone cancer	5.54e-05	0.000411	CcSEcCtD
Dasatinib—Headache—Epirubicin—bone cancer	5.5e-05	0.000409	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—bone cancer	5.38e-05	0.000399	CcSEcCtD
Dasatinib—Nausea—Epirubicin—bone cancer	5.22e-05	0.000388	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—bone cancer	5.17e-05	0.000384	CcSEcCtD
Dasatinib—Rash—Doxorubicin—bone cancer	5.13e-05	0.000381	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—bone cancer	5.12e-05	0.00038	CcSEcCtD
Dasatinib—Headache—Doxorubicin—bone cancer	5.09e-05	0.000378	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—bone cancer	4.83e-05	0.000359	CcSEcCtD
Dasatinib—FYN—Immune System—KIT—bone cancer	6.52e-06	3.63e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—BRAF—bone cancer	6.52e-06	3.63e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFBR2—bone cancer	6.51e-06	3.62e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—MDM2—bone cancer	6.5e-06	3.62e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—EGFR—bone cancer	6.49e-06	3.61e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SMO—bone cancer	6.42e-06	3.57e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	6.41e-06	3.57e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—JUN—bone cancer	6.38e-06	3.55e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—BRAF—bone cancer	6.38e-06	3.55e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.37e-06	3.54e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ENO2—bone cancer	6.35e-06	3.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KIT—bone cancer	6.28e-06	3.5e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFBR2—bone cancer	6.28e-06	3.49e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—EGFR—bone cancer	6.25e-06	3.48e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—MDM2—bone cancer	6.25e-06	3.48e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KIT—bone cancer	6.25e-06	3.48e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—MDM2—bone cancer	6.24e-06	3.47e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP9—bone cancer	6.23e-06	3.46e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KIT—bone cancer	6.2e-06	3.45e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFBR2—bone cancer	6.18e-06	3.44e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—EGFR—bone cancer	6.18e-06	3.44e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ATF1—bone cancer	6.17e-06	3.43e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—BRAF—bone cancer	6.15e-06	3.42e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—EGFR—bone cancer	6.12e-06	3.41e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—EGFR—bone cancer	6.1e-06	3.39e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—JUN—bone cancer	6.08e-06	3.39e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—EGFR—bone cancer	6.06e-06	3.37e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	6.03e-06	3.36e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—EGFR—bone cancer	6.03e-06	3.35e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KIT—bone cancer	6.02e-06	3.35e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL3—bone cancer	6.02e-06	3.35e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	6.01e-06	3.34e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ENO2—bone cancer	6e-06	3.34e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GSTP1—bone cancer	5.96e-06	3.32e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFBR2—bone cancer	5.95e-06	3.31e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—EGFR—bone cancer	5.95e-06	3.31e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—EGFR—bone cancer	5.93e-06	3.3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—MDM2—bone cancer	5.92e-06	3.29e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IGF1R—bone cancer	5.91e-06	3.29e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—DHFR—bone cancer	5.9e-06	3.28e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—EGFR—bone cancer	5.88e-06	3.27e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—GNA11—bone cancer	5.88e-06	3.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFBR2—bone cancer	5.88e-06	3.27e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—BRAF—bone cancer	5.87e-06	3.27e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MDM2—bone cancer	5.85e-06	3.25e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IGF1R—bone cancer	5.82e-06	3.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—EGFR—bone cancer	5.81e-06	3.23e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—EGFR—bone cancer	5.79e-06	3.22e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MDM2—bone cancer	5.77e-06	3.21e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KIT—bone cancer	5.75e-06	3.2e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—EGFR—bone cancer	5.73e-06	3.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KIT—bone cancer	5.73e-06	3.19e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—bone cancer	5.71e-06	3.18e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—bone cancer	5.68e-06	3.16e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—BRAF—bone cancer	5.66e-06	3.15e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—JUN—bone cancer	5.65e-06	3.14e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—bone cancer	5.62e-06	3.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IGF1R—bone cancer	5.6e-06	3.12e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—DHFR—bone cancer	5.57e-06	3.1e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTGS2—bone cancer	5.56e-06	3.1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF1R—bone cancer	5.53e-06	3.08e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—EGFR—bone cancer	5.53e-06	3.08e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GNA11—bone cancer	5.51e-06	3.07e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MDM2—bone cancer	5.46e-06	3.04e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ATF1—bone cancer	5.46e-06	3.04e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—EGFR—bone cancer	5.45e-06	3.03e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—JUN—bone cancer	5.43e-06	3.02e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KIT—bone cancer	5.43e-06	3.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—bone cancer	5.41e-06	3.01e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—BRAF—bone cancer	5.4e-06	3.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—BRAF—bone cancer	5.38e-06	2.99e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—EGFR—bone cancer	5.35e-06	2.98e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	5.35e-06	2.98e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.35e-06	2.97e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—bone cancer	5.34e-06	2.97e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—MDM2—bone cancer	5.33e-06	2.97e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL3—bone cancer	5.33e-06	2.96e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTGS2—bone cancer	5.27e-06	2.93e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—MDM2—bone cancer	5.22e-06	2.9e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GNA11—bone cancer	5.21e-06	2.9e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—MDM2—bone cancer	5.19e-06	2.89e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MDM2—bone cancer	5.16e-06	2.87e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFBR2—bone cancer	5.15e-06	2.86e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—JUN—bone cancer	5.14e-06	2.86e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—MDM2—bone cancer	5.14e-06	2.86e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—JUN—bone cancer	5.08e-06	2.83e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—EGFR—bone cancer	5.03e-06	2.8e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—EGFR—bone cancer	5.03e-06	2.8e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—EGFR—bone cancer	5.02e-06	2.79e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KIT—bone cancer	5.02e-06	2.79e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP3A4—bone cancer	5e-06	2.78e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—MDM2—bone cancer	4.95e-06	2.75e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MMP9—bone cancer	4.95e-06	2.75e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MDM2—bone cancer	4.92e-06	2.74e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MDM2—bone cancer	4.88e-06	2.72e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KIT—bone cancer	4.86e-06	2.7e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1R—bone cancer	4.84e-06	2.69e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—BRAF—bone cancer	4.82e-06	2.68e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—bone cancer	4.82e-06	2.68e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KIT—bone cancer	4.81e-06	2.68e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ENO2—bone cancer	4.8e-06	2.67e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—bone cancer	4.78e-06	2.66e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTGS2—bone cancer	4.74e-06	2.64e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MDM2—bone cancer	4.74e-06	2.64e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYP3A4—bone cancer	4.72e-06	2.63e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—BRAF—bone cancer	4.71e-06	2.62e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.7e-06	2.61e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—bone cancer	4.68e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—JUN—bone cancer	4.65e-06	2.59e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—bone cancer	4.64e-06	2.58e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—JUN—bone cancer	4.63e-06	2.58e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTGS2—bone cancer	4.57e-06	2.54e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—BRAF—bone cancer	4.57e-06	2.54e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFBR2—bone cancer	4.56e-06	2.54e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—JUN—bone cancer	4.54e-06	2.52e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MDM2—bone cancer	4.53e-06	2.52e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	4.52e-06	2.52e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—JUN—bone cancer	4.52e-06	2.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MDM2—bone cancer	4.51e-06	2.51e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—bone cancer	4.49e-06	2.5e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—JUN—bone cancer	4.48e-06	2.49e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—JUN—bone cancer	4.47e-06	2.49e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—DHFR—bone cancer	4.45e-06	2.48e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—bone cancer	4.44e-06	2.47e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KIT—bone cancer	4.44e-06	2.47e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KIT—bone cancer	4.38e-06	2.44e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MMP9—bone cancer	4.36e-06	2.43e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTGS2—bone cancer	4.35e-06	2.42e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—JUN—bone cancer	4.3e-06	2.39e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1R—bone cancer	4.29e-06	2.39e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KIT—bone cancer	4.28e-06	2.38e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—MDM2—bone cancer	4.28e-06	2.38e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTP1—bone cancer	4.27e-06	2.38e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—bone cancer	4.27e-06	2.38e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—bone cancer	4.27e-06	2.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—JUN—bone cancer	4.25e-06	2.36e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KIT—bone cancer	4.22e-06	2.35e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—BRAF—bone cancer	4.17e-06	2.32e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNA11—bone cancer	4.16e-06	2.31e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—bone cancer	4.14e-06	2.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—BRAF—bone cancer	4.11e-06	2.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KIT—bone cancer	4.06e-06	2.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—bone cancer	4.04e-06	2.25e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MDM2—bone cancer	4.04e-06	2.25e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTP1—bone cancer	4.04e-06	2.25e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—BRAF—bone cancer	4.03e-06	2.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KIT—bone cancer	4.01e-06	2.23e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—bone cancer	4e-06	2.22e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—BRAF—bone cancer	3.97e-06	2.21e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MDM2—bone cancer	3.95e-06	2.2e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—bone cancer	3.94e-06	2.19e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—JUN—bone cancer	3.93e-06	2.19e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—bone cancer	3.83e-06	2.13e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MMP9—bone cancer	3.83e-06	2.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MDM2—bone cancer	3.83e-06	2.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—BRAF—bone cancer	3.82e-06	2.12e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—bone cancer	3.81e-06	2.12e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MDM2—bone cancer	3.79e-06	2.11e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP3A4—bone cancer	3.77e-06	2.1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—BRAF—bone cancer	3.77e-06	2.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—bone cancer	3.73e-06	2.08e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—JUN—bone cancer	3.72e-06	2.07e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	3.66e-06	2.03e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—bone cancer	3.65e-06	2.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—bone cancer	3.64e-06	2.03e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—bone cancer	3.57e-06	1.98e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—DHFR—bone cancer	3.55e-06	1.98e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—bone cancer	3.55e-06	1.98e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—bone cancer	3.52e-06	1.96e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—JUN—bone cancer	3.51e-06	1.95e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KIT—bone cancer	3.51e-06	1.95e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—bone cancer	3.51e-06	1.95e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MDM2—bone cancer	3.5e-06	1.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MDM2—bone cancer	3.45e-06	1.92e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MMP9—bone cancer	3.42e-06	1.9e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—bone cancer	3.4e-06	1.89e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—bone cancer	3.38e-06	1.88e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MDM2—bone cancer	3.37e-06	1.88e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—bone cancer	3.37e-06	1.88e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—bone cancer	3.36e-06	1.87e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—bone cancer	3.36e-06	1.87e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—bone cancer	3.34e-06	1.86e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—JUN—bone cancer	3.33e-06	1.85e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MDM2—bone cancer	3.32e-06	1.85e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNA11—bone cancer	3.32e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—BRAF—bone cancer	3.3e-06	1.84e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—JUN—bone cancer	3.29e-06	1.83e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—bone cancer	3.24e-06	1.8e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—bone cancer	3.24e-06	1.8e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—bone cancer	3.22e-06	1.79e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MDM2—bone cancer	3.2e-06	1.78e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MDM2—bone cancer	3.16e-06	1.76e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—bone cancer	3.11e-06	1.73e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—bone cancer	3.09e-06	1.72e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—bone cancer	3.09e-06	1.72e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—bone cancer	3.08e-06	1.71e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—bone cancer	3.07e-06	1.71e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP3A4—bone cancer	3.01e-06	1.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—JUN—bone cancer	3e-06	1.67e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.99e-06	1.67e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—bone cancer	2.96e-06	1.65e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—bone cancer	2.95e-06	1.64e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—JUN—bone cancer	2.93e-06	1.63e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—bone cancer	2.92e-06	1.63e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—bone cancer	2.92e-06	1.63e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—bone cancer	2.91e-06	1.62e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JUN—bone cancer	2.89e-06	1.61e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—bone cancer	2.85e-06	1.59e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—bone cancer	2.81e-06	1.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—bone cancer	2.78e-06	1.55e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MDM2—bone cancer	2.77e-06	1.54e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—bone cancer	2.76e-06	1.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—bone cancer	2.74e-06	1.53e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—DHFR—bone cancer	2.74e-06	1.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—bone cancer	2.71e-06	1.51e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—bone cancer	2.7e-06	1.5e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—bone cancer	2.67e-06	1.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—bone cancer	2.61e-06	1.45e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—bone cancer	2.6e-06	1.44e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—bone cancer	2.59e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—bone cancer	2.57e-06	1.43e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNA11—bone cancer	2.56e-06	1.43e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—bone cancer	2.45e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—bone cancer	2.4e-06	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—bone cancer	2.39e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—bone cancer	2.36e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—bone cancer	2.34e-06	1.3e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—bone cancer	2.32e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—bone cancer	2.31e-06	1.28e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—bone cancer	2.27e-06	1.26e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—bone cancer	2.21e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—bone cancer	2.2e-06	1.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—bone cancer	2.19e-06	1.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—bone cancer	2.16e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—bone cancer	2.13e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—bone cancer	2.09e-06	1.16e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—bone cancer	2.07e-06	1.15e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—bone cancer	1.99e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—bone cancer	1.98e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—bone cancer	1.94e-06	1.08e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—bone cancer	1.91e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—bone cancer	1.89e-06	1.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—bone cancer	1.84e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—bone cancer	1.81e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—bone cancer	1.67e-06	9.31e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—bone cancer	1.67e-06	9.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—bone cancer	1.59e-06	8.83e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—bone cancer	1.4e-06	7.82e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—bone cancer	1.33e-06	7.42e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—bone cancer	1.03e-06	5.73e-06	CbGpPWpGaD
